title: Safety of urate-lowering therapies: managing the risks to gain the benefits.
abstract: Gout is a metabolic disorder of purine metabolism and uric acid elimination. Over time, acute gout can develop into a chronic, disabling arthropathy, often associated with multiple comorbidities. Gout patients have often been undertreated, partly because of the clinician's perceived risks of a therapy outweighing its potential benefits. The approval of new therapies to treat hyperuricemia in gout has led to a new understanding of gout management and medication safety regarding new and old therapies. This review focuses on potential safety issues of currently available urate-lowering therapies and outlines strategies to minimize risks so their benefits can be reached.
authors.affiliation: Duke Gout and Crystal Arthropathies Clinic, Duke Specialty Infusion Center, Durham, NC 27710, USA. robert.keenan@duke.edu
authors.forename: Robert T
authors.initials: RT
authors.lastname: Keenan
mesh_terms: D000493:Allopurinol / Q000008:administration & dosage / Q000009:adverse effects*; D015897:Comorbidity; D000069465:Febuxostat; D006073:Gout / Q000097:blood / Q000188:drug therapy* / Q000453:epidemiology; D006074:Gout Suppressants / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D033461:Hyperuricemia / Q000097:blood / Q000188:drug therapy* / Q000453:epidemiology; D012307:Risk Factors; D013844:Thiazoles / Q000008:administration & dosage / Q000009:adverse effects*; D014527:Uric Acid / Q000097:blood
chemical_list: D006074:Gout Suppressants; D013844:Thiazoles; D000069465:Febuxostat; D014527:Uric Acid; D000493:Allopurinol